AR and pachyonychia congenita: Currently, there are no FDA‐approved PAM inhibitors for PC, but several PAM inhibitors (e.g. samotolisib, everolimus, capivasertib) have been or are currently being evaluated in phase 2/3 PC clinical trials in combination with AR signaling inhibitors [2].